by Emily Mullin | Nov 29, 2023 | Uncategorized
CAR-T cell therapy harnesses the immune system to attack blood cancers. Six years after approving the first treatment, the FDA is investigating whether it can give rise to secondary cancers.
by Emily Mullin | Nov 27, 2023 | Uncategorized
The FDA has yet to approve any drugs for life extension. But biotech company Loyal is now a step closer to bringing one to market—for dogs.
by Emily Mullin | Nov 16, 2023 | Uncategorized
The gene-editing therapy, called Casgevy, uses Crispr to prevent debilitating pain in patients with sickle cell disease. It also eliminates the need for regular blood transfusions in people with beta thalassemia.
by Emily Mullin | Nov 14, 2023 | Uncategorized
It’s still early days for a novel form of gene therapy called base editing, but this small study in people with extremely high cholesterol shows striking results.
by Emily Mullin | Nov 11, 2023 | Uncategorized
The drug semaglutide is already widely used for weight loss. Now its maker is presenting new evidence that it can reduce cardiovascular illnesses and deaths.
